sept8a Antibody

What is SEPT8 and what cellular functions does it perform?

SEPT8 (Septin 8) is a member of the septin family of nucleotide binding proteins, initially characterized in yeast as cell division cycle regulatory proteins. Septins are highly conserved across species including yeast, Drosophila, and mammals. They play crucial roles in regulating cytoskeletal organization, which is essential for multiple cellular processes .

SEPT8 functions as part of septin ring structures that are essential for cell cycle progression and vesicle sorting . At the molecular level, SEPT8 is a filament-forming cytoskeletal GTPase. It appears to participate in the process of SNARE complex formation in synaptic vesicles and may play a role in platelet secretion . Some isoforms, particularly isoform 4, stabilize BACE1 protein levels and promote the sorting and accumulation of BACE1 to recycling or endosomal compartments, thereby modulating the beta-amyloidogenic processing of APP .

Disruption of septin function, including SEPT8, disturbs cytokinesis and results in large multinucleate or polyploid cells . This highlights the critical importance of septins in maintaining cellular integrity during division.

What applications are suitable for anti-SEPT8 antibodies?

Based on validated research data, anti-SEPT8 antibodies have been successfully employed in multiple applications:

For Western blot applications, HCT116 and HeLa cell lysates have been used as positive controls, with an expected band size of approximately 54-56 kDa . For immunofluorescence applications, methanol-fixed HeLa cells have been successfully used to visualize SEPT8 localization patterns .

What species reactivity can be expected with anti-SEPT8 antibodies?

The reactivity of anti-SEPT8 antibodies varies by product. Based on the available research data:

It's important to note that cross-reactivity with orthologous proteins from other species (including sept8a in zebrafish or other model organisms) should be experimentally validated, even when significant sequence homology exists.

How can I validate the specificity of an anti-SEPT8 antibody?

Antibody validation is critical for ensuring reliable experimental results. For SEPT8 antibodies, two primary validation approaches are recommended:

Genetic Approaches:

• Knockout (KO) cell lines: Generate SEPT8 knockout cells using CRISPR-Cas9 or similar technology and confirm the absence of signal compared to wild-type cells .

• RNA interference: Use siRNA or shRNA to knockdown SEPT8 expression and demonstrate corresponding reduction in antibody signal .

Orthogonal Approaches:

• Correlation with GFP-tagged SEPT8 expression: Compare antibody staining patterns with GFP-tagged SEPT8 localization .

• Mass spectrometry validation: Confirm the identity of proteins recognized by the antibody through immunoprecipitation followed by mass spectrometry .

Recent research has demonstrated that genetic validation approaches (particularly using knockout controls) provide more reliable validation than orthogonal approaches. For immunofluorescence applications, only 38% of antibodies validated using orthogonal strategies were confirmed when tested against knockout cells, compared to 80% of antibodies validated using genetic strategies .

What are the appropriate positive controls for SEPT8 detection?

Based on validated research:

• For Western blot:

  • HeLa whole cell lysates (human cervical cancer cell line)

  • HCT116 whole cell lysates (human colorectal carcinoma cell line)

• For Immunofluorescence:

  • Methanol-fixed HeLa cells, where SEPT8 can be visualized in comparison with cytoskeletal markers like alpha-tubulin

When establishing a new experimental system, it is advisable to include these positive controls alongside your experimental samples to confirm antibody performance.

How do I troubleshoot non-specific binding with anti-SEPT8 antibodies?

Non-specific binding is a common challenge when working with antibodies. For SEPT8 antibodies, consider the following troubleshooting approaches:

• Optimize antibody concentration:

  • Perform a dilution series to determine the optimal antibody concentration that maximizes specific signal while minimizing background .

  • Start with the manufacturer's recommended dilution (typically 1/2000 for Western blot or 1/200 for immunofluorescence) and adjust as needed .

• Blocking optimization:

  • Extend blocking time or use alternative blocking agents (BSA, normal serum, commercial blockers) to reduce non-specific binding.

  • For highly hydrophobic proteins like septins, adding 0.1-0.3% Triton X-100 to blocking solutions may help reduce non-specific hydrophobic interactions .

• Increase washing stringency:

  • Use additional washing steps or higher detergent concentrations in wash buffers to remove weakly bound antibodies.

• Validate with genetic controls:

  • The most definitive approach is to compare with SEPT8 knockout or knockdown samples to distinguish between specific and non-specific signals .

How can predictive methods help assess anti-SEPT8 antibody performance?

Recent advances in antibody biophysical characterization can help predict antibody performance. These methods assess:

• Aggregation propensity:

  • Antibodies with high aggregation-prone regions (APRs) in complementarity-determining regions (CDRs) may show reduced specificity and increased background .

  • Computational tools like Solubis can predict aggregation tendencies, with scores above 300 associated with increased aggregation risk .

• Thermal stability:

  • Higher thermal stability correlates with better antibody performance in various applications .

  • Techniques like differential scanning fluorimetry (DSF) can assess thermal stability profiles.

• Colloidal stability:

  • Antibodies with poor colloidal stability may form aggregates that contribute to non-specific binding .

  • High-throughput methods can assess self-interaction and hydrophobicity characteristics.

These predictive methods are increasingly being incorporated into antibody development pipelines, allowing researchers to select antibodies with optimal biophysical properties .

What buffer and storage conditions optimize anti-SEPT8 antibody performance?

The stability and performance of anti-SEPT8 antibodies depend on proper handling and storage:

Recommended storage conditions:

• For continuous use (up to one week): Store undiluted antibody at 2-8°C .

• For long-term storage: Aliquot and store at -20°C .

• Avoid storage in frost-free freezers, as temperature cycling can degrade antibody quality .

• Avoid repeated freeze/thaw cycles, which can lead to antibody denaturation and reduced activity .

Buffer composition:

• Typical buffer composition includes PBS (pH 7.3), 0.02% sodium azide, and 50% glycerol as a stabilizer .

• Before use, gently mix the antibody solution and consider briefly centrifuging the vial to collect contents .

How can I distinguish between SEPT8 and other septin family members?

Distinguishing between different septin family members is crucial for accurate experimental interpretation:

• Epitope selection:

  • Choose antibodies raised against unique regions of SEPT8. For example, ARG57905 targets amino acids 348-427 of human SEPT8, a region with lower homology to other septins .

• Molecular weight discrimination:

  • SEPT8 has an observed molecular weight of approximately 54 kDa on SDS-PAGE , which can help distinguish it from other septins with different molecular weights.

• Multiple antibody validation:

  • Use multiple antibodies targeting different epitopes of SEPT8 to confirm specificity.

  • If possible, include antibodies against other septins as controls to confirm distinct recognition patterns.

• Mass spectrometry confirmation:

  • For definitive identification, immunoprecipitated proteins can be analyzed by mass spectrometry to confirm the identity as SEPT8 rather than other septin family members .

How do post-translational modifications affect SEPT8 antibody recognition?

Post-translational modifications (PTMs) can significantly impact antibody recognition of SEPT8:

• Common SEPT8 modifications:

  • Septins are known to undergo phosphorylation, SUMOylation, and ubiquitination, which can alter epitope accessibility.

  • These modifications may vary by cell type, developmental stage, and cellular conditions.

• Impact on antibody binding:

  • Antibodies raised against unmodified recombinant proteins (like ARG57905) may not recognize heavily modified forms of SEPT8 in certain cellular contexts .

  • Phosphorylation-specific antibodies may be required for studies focused on activation-dependent regulation of SEPT8.

• Experimental considerations:

  • When studying SEPT8 in contexts where PTMs are relevant, consider using phosphatase inhibitors or other PTM-preserving approaches during sample preparation.

  • If possible, validate antibody recognition using in vitro modified SEPT8 proteins.

What techniques can effectively validate SEPT8 antibody specificity?

Research has demonstrated that independent validation of antibodies is essential, as many commercial antibodies do not perform as claimed . For SEPT8 antibodies, a systematic validation approach should include:

• Western blot validation:

  • Compare wild-type samples with SEPT8 knockout or knockdown samples.

  • Expected result: Clear band at ~54-56 kDa in wild-type samples that is absent or significantly reduced in knockout/knockdown samples .

• Immunofluorescence validation:

  • Compare staining patterns in wild-type and knockout cells.

  • Co-staining with established cytoskeletal markers can confirm expected localization patterns .

• Orthogonal validation:

  • Compare antibody staining with GFP-SEPT8 localization.

  • Verify specific interaction through immunoprecipitation followed by mass spectrometry .

Recent research involving validation of 614 commercial antibodies found that validation using genetic approaches (knockout/knockdown controls) was significantly more reliable than orthogonal approaches, with success rates of 80% versus 38% for immunofluorescence applications .

What fixation methods are optimal for SEPT8 immunostaining?

The choice of fixation method can significantly impact SEPT8 detection in immunostaining applications:

• Methanol fixation:

  • Successfully used for detecting SEPT8 in HeLa cells .

  • Preserves cytoskeletal structures while allowing antibody access to epitopes.

  • Typical protocol: 100% ice-cold methanol for 10 minutes at -20°C.

• Paraformaldehyde fixation:

  • Used for IHC-P applications with anti-SEPT8 antibodies .

  • May require antigen retrieval steps to expose epitopes masked by cross-linking.

• Dual fixation approach:

  • For challenging samples, a brief paraformaldehyde fixation (5 minutes) followed by methanol fixation can preserve both structural integrity and epitope accessibility.

When establishing a new immunostaining protocol for SEPT8, it is advisable to compare different fixation methods to determine which provides optimal signal-to-noise ratio in your specific experimental system.

How can I interpret variable results with SEPT8 antibodies across different experimental systems?

Variability in SEPT8 antibody performance across different experimental systems can be attributed to several factors:

• Expression level variations:

  • SEPT8 expression levels vary significantly across cell types and tissues.

  • In low-expressing systems, signal amplification methods may be required.

• Isoform specificity:

  • Multiple alternatively spliced transcript variants of SEPT8 exist, encoding different isoforms .

  • Confirm whether your antibody recognizes all or specific isoforms (e.g., isoform 4 has specific functions in BACE1 stabilization) .

• Technical variables:

  • Sample preparation method, protein extraction efficiency, and transfer efficiency (for Western blots) can all impact results.

  • Standardize protocols and include positive controls (e.g., HeLa lysates) to normalize between experiments .

• Antibody batch variations:

  • Polyclonal antibodies like ARG57905 and ab154112 may show batch-to-batch variations .

  • Consider validating new antibody lots against previously validated lots.

What are the common pitfalls in SEPT8 antibody-based experiments?

Research indicates several common pitfalls when working with antibodies that apply to SEPT8 studies:

• Inadequate validation:

  • Approximately 20-30% of protein studies use ineffective antibodies .

  • Always validate antibody specificity in your experimental system using genetic approaches where possible.

• Over-reliance on manufacturer claims:

  • Recent research found that many antibodies do not perform as claimed in manufacturer datasheets .

  • Independent validation is essential, particularly for critical research findings.

• Inappropriate controls:

  • Lack of proper positive and negative controls can lead to misinterpretation of results.

  • For SEPT8, include known positive samples (e.g., HeLa cells) and, when possible, SEPT8-depleted negative controls .

• Non-optimized protocols:

  • Using standardized protocols without optimization for SEPT8 detection can lead to poor results.

  • Optimize antibody concentration, incubation times, and detection methods for your specific application.